35 results about "Neurogenic Urinary Bladder" patented technology

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and / or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

This invention relates to the use of beta-3-adrenoceptor agonists for the prevention and treatment of kidney damage and / or functional bladder complaints, particularly bladder complaints of neurogenic origin as the result of spinal cord injury.

The invention provides a pharmaceutical composition containing sodium hyaluronate with the relatively medium molecular weight and chondroitin sulfate with the relatively low molecular weight. The molecular weight of sodium hyaluronate is 200 kD-1,000 kD, the concentration of sodium hyaluronate is 1%-2%, the molecular weight of chondroitin sulfate is 5 kD-10 kD, and the concentration of chondroitin sulfate is 1.5%-3%. The pharmaceutical composition contains chondroitin sulfate with the relatively low molecular weight, has the better treatment effect than single sodium hyaluronate and can be used for treating refractory nonbacterial cystitis, Chronic recurrent bacterial cystitis, radiation-induced cystitis, interstitial cystitis (the chronic bladder pain syndrome) and neurogenic bladder urinary system infection.

There is provided an agent comprising solifenacin succinate in an amount of 5 mg to 10 mg or solifenacin or a pharmaceutically acceptable salt thereof in an amount equimolar to 5 mg to 10 mg of solifenacin succinate for improvement of urinary urgency, pollakiuria and urinary incontinence due to neurogenic bladder caused by neurodegenerative diseases such as cerebrovascular disease or cerebral infarction, brain or spinal cord injury due to trauma, multiple sclerosis, Parkinson's disease, congenital malformation of the nerve system, peripheral neuropathy, and various spine lesions, that is, spinal cord compression and injury due to fracture, cervical and lumbar spondylosis, spondylosis deformans, spondylolisthesis, spinal stenosis, vertebral disk hernia and the like.

A therapeutic agent for voiding dysfunction associated with neurogenic bladder where said agent contains tamsulosin or a pharmaceutically acceptable salt thereof.

The present invention relates to medical equipment technology, and is especially one kind of neurogenic bladder urination alarm. The neurogenic bladder urination alarm consists of one permanent magnet and one alarm device. The alarm device consists of one alarm switch, one buzzer, one power switch and one power source connected with one wire. The alarm switch consists of one dial, one central fulcrum, one side fulcrum and one pointer, and the wire has one end connected to the power switch and the other end connected to the side fulcrum. The permanent magnet and the alarm device are fixed separately to the bladder wall and the inferior belly wall. After the power switch is turned on, the permanent magnet moves upwards with the increased urea amount inside the bladder to drive the pointer, and when the pointer contacts with the side fulcrum, the circuit is closed, the buzzer sounds to alarm an urination signal. The present invention is for neurogenic bladder patient.

The invention relates to a training device for evaluating pressure and volume of a bladder. The training device for evaluating pressure and volume of the bladder comprises a medical trolley, wherein a suspension bottle is arranged at the upper part of the medical trolley, a main guide pipe used for perfusion is arranged on the suspension bottle, and a three-way reversing valve is arranged at the tail end of the main guide pipe; a side panel is arranged at one side of the middle part of the medical trolley, a drip chamber is arranged on the main guide pipe, a clamping device used for clamping the drip chamber is arranged at the upper part of the side panel, and an extrusion mechanism is arranged on the side panel below the clamping device; and a control panel is arranged on the medical trolley below the side panel. The training device for evaluating the pressure and volume of the bladder can be used for continuously and intermittently determining pressure in the bladder, abdominal pressure and detrusor pressure variation and drawing dynamic change of relation between pressure and volume, can detect detrusor hyperreflexia and has a good training effect on neurogenic bladder functional disorder. The training device for evaluating the pressure and volume of the bladder is reasonable in structural design and easy to move, and medical expense can be greatly reduced for a patient, so that burden of the patient is reduced.

The invention discloses a neurogenic bladder auxiliary device. The neurogenic bladder auxiliary device comprises a fixing block fixed to a specific position, wherein a pushing and pressing device anda sucking device are separately mounted at the upper part and the lower part of the fixing block, and are mutually effected through the up-and-down moving of a moving rod; the pushing and pressing device comprises an upper moving block which is fixed to the moving rod; the upper moving block is located above the fixing block; two connecting rods which are mutually hinged are respectively hinged tothe upper moving block and the fixing block; and a roller is also rotatably connected to a hinging position of the two connecting rods. According to the neurogenic bladder auxiliary device disclosedby the invention, a patient or medical personnel can push and press the moving rod through a hand supporting cushion; the moving rod moves downwards, and the motion of pushing and pressing can be performed on the lower abdomen of the patient through the pushing and pressing device; and the motion of pushing and pressing is acted on the bladder, so that the bladder pressure can be enlarged to stimulate micturition desire, and the smoothness degree of urination is improved.

The invention discloses a medicine for treating neurogenic bladder to solve the problem of treatment of neurogenic bladder. The medicine is characterized by being processed by the following traditional Chinese medicines by weight: 6-10 parts of catclaw buttercup root, 8-15 parts of fiveleaf akebia fruit, 8-15 parts of lance asiabell root, 6-10 parts of stringy stonecrop herb, 6-10 parts of largehead atractylodes rhizome, 8-15 parts of adsuki bean, 6-10 parts of common anemarrhena rhizome, 8-15 parts of immature orange fruit and 3-6 parts of dried ginger. Clinical experiments prove that used for treating neurogenic bladder, the medicine has the characteristics of good curative effect and higher safety and deserves clinical application and promotion.

The invention relates to the technical field of biomedicine, in particular to application of amniotic epithelial cells and cell preparations thereof. The invention discloses application of the amniotic epithelial cells in preparation of a medicament for treating neurogenic bladder and cell preparations of the medicament for treating spinal neurogenic bladder. The amniotic epithelial cells or the cell preparations containing the amniotic epithelial cells can effectively treat or improve the neurogenic bladder, particularly spastic neurogenic bladder, and improve or recover the physiological function of the bladder; meanwhile, the amniotic epithelial cells have wide sources, so that the phenomenon of ethic or morality is avoided. Therefore, the amniotic epithelial cells and the cell preparations provide a new effective choice for clinical treatment of the neurogenic bladder in the future.

The various embodiments disclosed here relate to systems, methods, and devices for monitoring bladder health via pressure. Certain implementations are directed to patients who require daily catheterization. The various embodiments have at least one tube coupled to a catheter, a pressure sensor and a processor. Further implementations feature an optional pump and measure volume. Certain embodiments include a digital device with a software application capable of displaying the monitored readings.

The invention discloses a pair of patient trousers suitable for a patient bundled with a urine bag for a long period. The pair of patient trousers comprises a trousers body and covering cloth, wherein the trousers body comprises a waistband and trousers legs connected onto the waistband; an opening is formed in the front surface of the trousers body from the bottom of a crotch to the top and extends to the middle part of the waistband; ribbons are arranged on the trousers body and on the two sides of the opening; the covering cloth covers the opening, is in an isosceles trapezoid shape and comprises two short edges which are parallel to each other and long edges; the short edges of the covering cloth are sewed on the trousers body and above the opening; button holes are formed in the two sides of the long edges of the covering cloth; and buttons are fixed at the parts, corresponding to the button holes, on the trousers legs. With the adoption of the manner, the pair of patient trousers can be applicable to male patients who have neurogenic bladders and cognitive disorders, and need to be bundled with urine bags for a long period, and troubles that conventional urine bags are not easy to observe and replace are solved.

The invention discloses a training bed for treating a patient suffering from neurogenic bladder. The training bed comprises a bed body framework, a bed plate, a bed pan, a funnel, a spray nozzle, an adjustable fixing rod and a capacity measurement bag, wherein the bed plate is put on the bed body framework and comprises an upper plate, a middle plate, a lower plate, a rocker system and a hand crank, the upper plate, the middle plate and the lower plate are fixed through hinges, the rocker system is arranged at the lower part of the bed plate, and the hand crank is connected with the rocker system to control the upper plate, the middle plate and the lower plate; the bed pan is embedded in the lower plate, a water outlet is formed in the lower part of the bed pan and connected with a guide pipe, and the guide pipe is connected with the capacity measurement bag; the adjustable fixing rod is arranged on one side of the bed body framework, the funnel is fixed at the top of the adjustable fixing rod, and the lower part of the funnel is connected with the spray nozzle through a pipeline. The training bed is novel in structure and convenient to use, makes the patient feel comfortable when the bladder capacity of the patient suffering from neurogenic bladder is trained and measured, can ensure that a measured liquid leaks into a urine receiving container and can accurately measure the capacity and clean the perineum of the patient after capacity measurement, and accordingly, infection is reduced.

The present invention provides a compound that can be used as an MC4 receptor agonist. The inventors study MC4 receptor agonists, and confirm that a piperazine derivative has an action, thereby perfecting the present invention. Specifically, this piperazine derivative has an MC4 receptor agonist action and can be used as an agent for the prevention and / or treatment of bladder and urinary tract diseases, especially underactive bladder, hypotonic bladder, noncontracting bladder, detrusor muscle hypoactivity, neurogenic bladder, urethral relaxation failure, detrusor-external sphincter incoordination, and dysuria in benign prostatic hyperplasia.

To provide a compound useful as an MC4 receptor agonist. The present inventors have made studies on MC4 receptor agonists. As a result, it is confirmed that a piperazine derivative has an MC4 receptoragonist activity, which leads to the accomplishment of the present invention. The piperazine derivative according to the present invention has an MC4 receptor agonist activity, and therefore can be used as a prophylactic or therapeutic agent for disturbance of urination in bladder and urinary tract diseases, particularly underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-sphincter dyssynergia and prostatic hyperplasia.

The invention discloses a traditional Chinese medicinal compound composition for treating neurogenic bladder disorders. The composition is prepared from the following materials: 10 to 30 parts of coix seeds, 10 to 30 parts of scrophularia ningpoensis, 10 to 30 parts of astragalus membranaceus, 10 to 30 parts of atractylodes macrocephala, 10 to 30 parts of cornus officinalis, 10 to 30 parts of mantis egg case, 10 to 30 parts of rhizoma acori graminei, 2 to 10 parts of manis pentadactyla, 5 to 15 parts of alisma plantago-aquatica, 5 to 25 parts of semen plantaginis, 10 to 30 parts of rhizoma dioscoreae colletii, 10 to 30 parts of dried pyrrosia lingua leaves, 10 to 30 parts of tetrapanax papyriferus, 10 to 30 parts of lysimachia christinae hance, 10 to 30 parts of radix stephaniae tetrandrae, 10 to 30 parts of dried laminaria sporophytes, 10 to 25 parts of dried pyrrosia lingua leaves and 10 to 30 parts of gardenia jasminoides. According to the invention, the raw material compatibility prescription is selected based on traditional Chinese medical theory, and the compatibility of all components is scientific and reasonable; experimental results show that the traditional Chinese medicinal compound composition can effectively improve urinary tract symptoms and urodynamic related indicators, effectively restore the lower urinary tract function and reduce the bladder residual urine volume, and has a good curative effect on neurogenic bladder disorders.

Described herein, to overcome the limitations of conventional antibiotics, antibiotics have been encapsulated in biocompatible particles manufactured using Particle Replication In Non-wetting Templates (PRINT). These PRINT antibiotic particles were assessed as a topical agent to prevent E. coli infection using in vitro and in vivo models relevant to UTI and neurogenic bladder. The results show a prolonged efficacy and wide distribution in the bladder, resulting in a prophylactic environment in the bladder. The subject matter described herein is directed to molded particles containing an antibiotic active agent and methods of treating diseases and conditions with the particles, and methods of preparing the particles and compositions comprising the particles.

The present invention relates to medical equipment technology, and is especially one kind of neurogenic bladder urination alarm. The neurogenic bladder urination alarm consists of one permanent magnet and one alarm device. The alarm device consists of one alarm switch, one buzzer, one power switch and one power source connected with one wire. The alarm switch consists of one dial, one central fulcrum, one side fulcrum and one pointer, and the wire has one end connected to the power switch and the other end connected to the side fulcrum. The permanent magnet and the alarm device are fixed separately to the bladder wall and the inferior belly wall. After the power switch is turned on, the permanent magnet moves upwards with the increased urea amount inside the bladder to drive the pointer, and when the pointer contacts with the side fulcrum, the circuit is closed, the buzzer sounds to alarm an urination signal. The present invention is for neurogenic bladder patient.

The invention discloses an electrical stimulation device for treating a neurogenic bladder. The device comprises a pair of shorts, an electrical stimulation device and a pressure sensing controller; athrough hole is formed in the crotch of the shorts, and the shorts are fixedly connected with an air bag sleeve through the through hole; the surface of the air bag sleeve is fixedly connected with aregulation and control device; the regulation and control device comprises a first shell; the surface of the first shell is fixedly connected with the front side of the shorts; an air inlet through groove is formed in the top of the first shell; a through hole is formed in the bottom of the first shell; and an air guide pipe is fixedly connected to the bottom of the first shell in a sealed mode through the through hole. According to the invention, the above structures are used in cooperation, so that the problem that in the actual use process, a traditional condom is difficult to meet the requirements of different users and an electrode is difficult to make full contact with the surface of a penis is solved; and meanwhile, the problem that erection occurs due to psychological reasons of apatient, external environment stimulation and sleeping at night, adaptive size adjustment of a traditional condom is difficult, and inconvenience is brought to use can also be solved.

Provided can be used as MC 4 Agonist compounds. MC 4 Receptor agonists were studied and it was confirmed that piperazine derivatives have MC 4 receptor agonist action, thus completing the present invention. The piperazine derivatives of the present invention have MC 4 Receptor agonist action, can act as bladder, urological disorders, especially hypoactive bladder, hypotonic bladder, non-contracting bladder, detrusor hypoactivity, neurogenic bladder, urethral insufficiency, detrusor-extraurethral Prophylactic or therapeutic agent use for sphincter dyssynergia and voiding disorder in prostatic hypertrophy.

The present invention relates to methods for reducing the frequency of bladder contractions without significantly affecting micturition pressure, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt or prodrug thereof. The method can be used to treat bladder dysfunction without significantly increasing residual volume, including urgency, frequency, pollakiuria, nocturia, low deferment time, suboptimal volume threshold, neurogenic bladder, or combinations thereof.

The present invention provides the ability to be used as MC 4 Compounds used as agonists. MC 4 Research on receptor agonists was carried out, and the effect of piperazine derivatives was confirmed, thereby completing the present invention. That is, the piperazine derivatives of the present invention have MC 4 Receptor agonist action, can be used as bladder and urinary tract diseases, especially hypoactive bladder, hypotonic bladder, non-contracting bladder, detrusor hypoactivity, neurogenic bladder, urethral insufficiency, detrusor extraurethral Prophylactic and / or therapeutic agent use for sphincter dyssynergia and voiding disorders in benign prostatic hypertrophy.

The invention relates to the field of medicine formulas for treating diabetic neurogenic bladder disease and particularly discloses a compound traditional Chinese medicine decoction used for treating the diabetic neurogenic bladder disease. The traditional Chinese medicine decoction is characterized by being prepared from the following raw materials, by weight, 20-25% of prepared rehmannia root, 10-13% of Chinese yam, 10-13% of cornus officinalis, 4-7% of monkshood, 4-7% of cinnamon, 4-7% of cassia twigs, 7-10% of rhizoma alismatis, 7-10% of poria cocos, 7-10% of atractylodes macrocephala, 4-7% of radix ophiopogonis and 4-7% of schisandra chinensis. The decoction is prepared by uniformly mixing the raw materials, soaking the raw materials in water, decocting the raw materials, removing residues to obtain a filtrate, sterilizing the filtrate and extracting the filtrate to obtain the decoction mixture, wherein the sum of the percentage ratio of the raw materials is 100%.

The invention relates to the technical field of biological medicines. The bladder overactivity is presented clinically with frequent micturition and urgent urination, and also appears in neurogenic bladder, overactive bladder, bladder outlet obstruction, interstitial cystitis and other diseases. A polypeptide micromolecule capable of inhibiting the activity of a P2X3 acceptor is provided and has an amino acid sequence as shown in SEQ ID NO.: 1. The invention also provides application of the polypeptide micromolecule in preparation of a medicine for preventing and treating bladder overactivity.

The invention belongs to the technical field of experimental model preparation, and discloses a rat spinal-cord-injured neurogenic bladder model and a preparation method of the rat spinal-cord-injured neurogenic bladder model. The preparation method comprises the steps that first, spinal cord transection is carried out on T10 / 11 intervertebral spaces of a first group of rats and the L2 / 3 intervertebral spaces of a second group of rats through a spinal cord transection method to form a segment-above-sacrum injury group and a sacral cord segment injury group respectively; second, operation nursing is carried out on the segment-above-sacrum injury group and the sacral cord segment injury group respectively; third, the spinal-cord-injured neurogenic bladder model is formed by selecting rats from the first group of rats and rats from the second group of rats according to preset conditions. According to the preparation method, the systematic spinal-cord-injured neurogenic bladder model is obtained, and the problems that the death rate of model rats after modeling is high and the occurrence rate of complications is high are solved.

Embodiments of the invention provide apparatus, systems and methods for stimulating tissue in the urinary tract to initiate or facilitate urination. One embodiment provides an external urinary sphincter stimulation (EUSS) catheter for stimulating the external urinary sphincter (EUS), where the EUSS catheter includes nerve stimulation electrodes (NSES) for delivering current to nerves within or around the EUS in order to relax the EUS prior to urination. Other embodiments provide a system for stimulating the EUS including the EUSS catheter and a controller operatively coupled to the EUSS catheter, where the controller includes a pulse generator for delivering current to the NSES. Other embodiments provide methods for positioning the EUSS catheter in the patient's body including in the EUS using a urethral approach. Embodiments of the invention are particularly useful for initiating and / or controlling urination for patients who have lost the ability to voluntarily urinate due to neurogenic bladder dysfunction.

The invention relates to the technical field of biological medicines. The bladder overactivity is presented clinically with frequent micturition and urgent urination, and also appears in neurogenic bladder, overactive bladder, bladder outlet obstruction, interstitial cystitis and other diseases. A polypeptide micromolecule capable of inhibiting the activity of a P2X3 acceptor is provided and has an amino acid sequence as shown in SEQ ID NO.: 1. The invention also provides application of the polypeptide micromolecule in preparation of a medicine for preventing and treating bladder overactivity.

The present invention relates to a shRNA, carrier, kit and application thereof for knocking down TGF-β1. The shRNA of the present invention comprises two oligonucleotide chains, and the sequence of the oligonucleotide chains is as SEQ ID NO : Shown in 9~10. The shRNA, carrier or kit of the present invention can effectively reduce the expression of TGF-β1 from the mRNA level and protein level, inhibit the expression and Smads phosphorylation of TGF-β1, CTGF, α-SMA in detrusor muscle cells or bladder, thereby It effectively inhibits the fibrosis of detrusor muscle cells or bladder, and has a therapeutic effect on neurogenic bladder fibrosis.

The invention discloses an electrical stimulation device for treating a neurogenic bladder. The electrical stimulation device comprises electrical stimulation monomers and a binding belt body for coating the multiple electrical stimulation monomers. The electrical stimulation monomers comprise first monomers or second monomers. The binding belt body comprises a belt body main body made of silica gel materials, a plurality of concave bodies consistent with the monomer shells or the first monomers in shape and structure are formed in the belt body main body, and the section of the belt body main body is spindle-shaped. An internally-arranged accommodating cavity is formed in the belt body main body, and an adjusting air bag is placed in the internally-arranged accommodating cavity. The section of the belt body main body is spindle-shaped, the belt body main body can be more attached to the waist and back of a human body, when the human body receives electrical stimulation to treat flat lying or supine lying, the waist, abdomen and back have no foreign body sensation, and the pressure of the waist and abdomen can be released by adjusting the size of the internal air bag. The electrical stimulation device for treating the neurogenic bladder is simple in structure, the electrical stimulation monomers adopt two modes, namely a hard mode and a soft mode, and selection can be carried out according to different requirements, so that the treatment comfort of a patient is improved.

The invention provides a neurogenic bladder urodynamic examination and treatment system. The system includes a rubber hose, a catheter connector, a plastic urethral catheter, a monitoring and detecting system, a urine storage bag and a liquid outlet; the rubber hose is a three-cavity tube; the three-cavity tube also includes a urethral guide tube body, a glycerol injection tube body and a drug injection tube body; the glycerol injection tube body is led out of an outer tube of the rubber hose; the plastic urethral catheter is directly connected with a rubber urethral catheter through the catheter connector, and the monitoring and detecting system is fixed on the plastic urethral catheter and composed of a flow meter, a pressure meter and a sensor. The outer tube of the rubber hose expand after being injected with glycerol through the glycerol injection tube body, and the tube can be fixed and is made to creep down due to the movement of a patient or gravity and other factors; sensor data of the monitoring and detecting system is displayed on mobile phones of medical staff through an APP, the medical staff can know the bladder function of the patient more accurately and conveniently at any time, a lot of manpower is saved, and delaying caused by manual operation is avoided.